(VIANEWS) – Meta Platforms (META), Intuitive Surgical (ISRG), CONMED Corporation (CNMD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Meta Platforms (META)
25.3% sales growth and 28.04% return on equity
Some other top-ranked stocks from the broader technology sector are CrowdStrike Holdings (CRWD Quick QuoteCRWD – Free Report) , Amazon.com (AMZN Quick QuoteAMZN – Free Report) and Meta Platforms (META Quick QuoteMETA – Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present.
These are Nvidia (NVDA Quick QuoteNVDA – Free Report) , Eli Lilly and Company (LLY Quick QuoteLLY – Free Report) , Meta Platforms (META Quick QuoteMETA – Free Report) , Uber Technologies, Inc (UBER Quick QuoteUBER – Free Report) and Ralph Lauren Corp. (RL Quick QuoteRL – Free Report) .
Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California
Earnings Per Share
As for profitability, Meta Platforms has a trailing twelve months EPS of $14.86.
PE Ratio
Meta Platforms has a trailing twelve months price to earnings ratio of 31.67. Meaning, the purchaser of the share is investing $31.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.04%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.7%, now sitting on 134.9B for the twelve trailing months.
Yearly Top and Bottom Value
Meta Platforms’s stock is valued at $470.61 at 15:22 EST, below its 52-week high of $488.62 and way higher than its 52-week low of $167.66.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 21, 2024, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 0.42%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Meta Platforms’s EBITDA is 8.74.
2. Intuitive Surgical (ISRG)
13.7% sales growth and 14.83% return on equity
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Intuitive Surgical has a trailing twelve months EPS of $5.04.
PE Ratio
Intuitive Surgical has a trailing twelve months price to earnings ratio of 74.77. Meaning, the purchaser of the share is investing $74.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.83%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Intuitive Surgical’s EBITDA is 17.99.
Yearly Top and Bottom Value
Intuitive Surgical’s stock is valued at $376.86 at 15:22 EST, under its 52-week high of $392.00 and way higher than its 52-week low of $222.65.
Sales Growth
Intuitive Surgical’s sales growth is 17.1% for the current quarter and 13.7% for the next.
3. CONMED Corporation (CNMD)
11.7% sales growth and 8.36% return on equity
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Earnings Per Share
As for profitability, CONMED Corporation has a trailing twelve months EPS of $2.04.
PE Ratio
CONMED Corporation has a trailing twelve months price to earnings ratio of 41.1. Meaning, the purchaser of the share is investing $41.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.36%.
Moving Average
CONMED Corporation’s worth is way below its 50-day moving average of $102.48 and way under its 200-day moving average of $111.05.
4. Red Rock Resorts (RRR)
11% sales growth and 355.8% return on equity
Red Rock Resorts, Inc., through its interest in Station Holdco and Station LLC, develops and operates casino and entertainment properties in the United States. It operates through two segments, Las Vegas Operations and Native American Management. The company owns and operates 9 gaming and entertainment facilities, and 10 smaller casinos in the Las Vegas regional market. In addition, it manages Graton Resort & Casino in northern California. As of December 31, 2021, it operated approximately 13,894 slot machines, 240 table games, and 3,081 hotel rooms in the Las Vegas market. The company was formerly known as Station Casinos Corp. and changed its name to Red Rock Resorts, Inc. in January 2016. Red Rock Resorts, Inc. was incorporated in 1976 and is based in Las Vegas, Nevada.
Earnings Per Share
As for profitability, Red Rock Resorts has a trailing twelve months EPS of $3.48.
PE Ratio
Red Rock Resorts has a trailing twelve months price to earnings ratio of 15.87. Meaning, the purchaser of the share is investing $15.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 355.8%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Red Rock Resorts’s EBITDA is 35.38.
Sales Growth
Red Rock Resorts’s sales growth is 10.8% for the current quarter and 11% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 34.9% and 28.9%, respectively.
5. STERIS (STE)
5.4% sales growth and 9.11% return on equity
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Earnings Per Share
As for profitability, STERIS has a trailing twelve months EPS of $5.69.
PE Ratio
STERIS has a trailing twelve months price to earnings ratio of 40.35. Meaning, the purchaser of the share is investing $40.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.11%.
